Last edition
News about "metabolic dysfunction-associated steatohepatitis ("
Roche to Acquire 89bio in Deal Worth Up to USD 3.5 Billion
Roche has entered into a merger agreement to acquire 89bio, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases.
Metabolic Dysfunction-associated Steatohepatitis ( | 18/09/2025 | By Dineshwori
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Metabolic Dysfunction-associated Steatohepatitis ( | 16/08/2025 | By Dineshwori | 121
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy